Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 74Kidney Neoplasms 27Prostatic Neoplasms 16Neoplasm Metastasis 11Urinary Bladder Neoplasms 5Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Neuroendocrine Tumors 3Carcinoma, Transitional Cell 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Margins of Excision 2Insulinoma 2Glucagonoma 2Gastrinoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Islet Cell 2Urothelial Cancer 1Ureteral Neoplasms 1Tuberous Sclerosis 1Thrombocytosis 1Testicular Neoplasms 1Renal Cell Cancer Metastatic 1Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1Primary Myelofibrosis 1

Interventions

Everolimus 2varlilumab 1Sunitinib 1Microscopy, Confocal 1Interferon alpha-2 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Margins of Excision × Everolimus × Genitourinary × Clear all
NCT01784978 2017-10-02

SUNRISES

Associació per a la Recerca Oncologica, Spain

Phase 2 Terminated
41 enrolled
Genitourinary

Margins of Excision, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡